This is stated in a press release from the company.
BioNTech today announced the launch of its malaria project, which will develop a well-tolerated and highly effective malaria vaccine and ensure a sustainable vaccine supply across the African continent, according to a press release.
It is noted that it is planned to select the most promising samples for the start of clinical trials by the end of 2022.
In addition, BioNTech also intends to begin clinical trials of a tuberculosis vaccine in 2022.
Large trials of the world's first malaria vaccine were completed in 2019, but WHO did not give it widespread use due to its low effectiveness.
Earlier, the President of the European Commission (EC) Ursula von der Leyen said that the European Union intends to create capacities for the production of vaccines against infectious diseases in Africa and allocate € 1 billion for this purpose.
At the end of June, it was reported that the WHO issued China a certificate confirming the country's "malaria-free" status.